{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:15:56Z","timestamp":1787584556116,"version":"build-2736575974"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>The aim of this study was to investigate the cost-effectiveness of bortezomib, melphalan and prednisone with daratumumab (D-VMP) versus bortezomib, melphalan and prednisone (VMP) in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem-cell transplantation (ASCT).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A Markov model was established and three exclusive health states, progression-free survival (PFS), progressive disease (PD) and death were included. The cycle length was set at 1.5 months and the time horizon was set at 20 years. The efficacy data were derived from the ALCYONE trial, and the utility values were obtained from previously published studies. The discount rate in the model was 3% per annum, and the willingness-to-pay (WTP) threshold was set at $150 000.00\/quality-adjusted life year (QALY) in the USA. Moreover, one-way and probabilistic sensitivity analyses were performed to evaluate the parameter uncertainty.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>D-VMP achieved an effectiveness of 6.91 QALYs at a cost of $858 695.42, while VMP achieved an effectiveness of 4.70 QALYs at a cost of $357\u2009387.82. The incremental effectiveness and cost of D-VMP versus VMP were 2.21 QALYs and $501 307.6, yielding an incremental cost-effectiveness ratio (ICER) of US $226 836.02\/QALY. The cost of daratumumab, utility for PFS, cost of subsequent therapies in the VMP group and cost of subsequent therapies in the D-VMP group were the most influential factors, and the probabilities of D-VMP and VMP as the cost-effective option were 0% and 100% at the WTP threshold of $150 000.00\/QALY, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Compared with VMP, D-VMP is unlikely to be a cost-effective regimen for patients with NDMM who are ineligible for ASCT from the US payer\u2019s perspective.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2023-076914","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:05:50Z","timestamp":1739995550000},"page":"e076914","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation"],"prefix":"10.1136","volume":"15","author":[{"given":"Dan","family":"Xie","sequence":"first","affiliation":[{"name":"Prenatal Diagnosis Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China"},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4972-6412","authenticated-orcid":false,"given":"Peng-Fei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gastric Cancer Center, Division of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2025070104270738000_15.2.e076914.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122"},{"key":"2025070104270738000_15.2.e076914.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025070104270738000_15.2.e076914.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"2025070104270738000_15.2.e076914.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"2025070104270738000_15.2.e076914.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1853"},{"key":"2025070104270738000_15.2.e076914.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"2025070104270738000_15.2.e076914.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6180"},{"key":"2025070104270738000_15.2.e076914.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"2025070104270738000_15.2.e076914.9","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"2025070104270738000_15.2.e076914.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351"},{"key":"2025070104270738000_15.2.e076914.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"2025070104270738000_15.2.e076914.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"2025070104270738000_15.2.e076914.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"2025070104270738000_15.2.e076914.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"2025070104270738000_15.2.e076914.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30167-2"},{"key":"2025070104270738000_15.2.e076914.16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/cer-2019-0052","article-title":"Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China","volume":"8","author":"Lu","year":"2019","journal-title":"J Comp Eff Res"},{"key":"2025070104270738000_15.2.e076914.17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"key":"2025070104270738000_15.2.e076914.18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J Immunotherapy Cancer"},{"key":"2025070104270738000_15.2.e076914.19","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"key":"2025070104270738000_15.2.e076914.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.05.017"},{"key":"2025070104270738000_15.2.e076914.21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin Ther"},{"key":"2025070104270738000_15.2.e076914.22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.2021015220","article-title":"Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma","volume":"140","author":"Yamamoto","year":"2022","journal-title":"Blood"},{"key":"2025070104270738000_15.2.e076914.23","first-page":"1691","article-title":"Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma","volume":"27","author":"Narsipur","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"2025070104270738000_15.2.e076914.24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.608685","article-title":"Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma","volume":"12","author":"Cao","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025070104270738000_15.2.e076914.25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.clinthera.2021.05.015","article-title":"First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis","volume":"43","author":"Li","year":"2021","journal-title":"Clin Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-076914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:50:45Z","timestamp":1754495445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-076914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2023-076914"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-076914","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}